Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases

Since early 2020, the SARS-CoV-2 pandemic has a massive impact on health care systems worldwide. Patients with malignant diseases are assumed to be at increased risk for a worse outcome of SARS-CoV-2 infection, and therefore, guidance regarding prevention and management of the infection as well as s...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia 2020-06, Vol.34 (6), p.1487-1494
Main Authors: von Lilienfeld-Toal, Marie, Vehreschild, Jörg Janne, Cornely, Oliver, Pagano, Livio, Compagno, Francesca, Hirsch, Hans H
Format: Article
Language:English
Subjects:
B cells
Betacoronavirus
Cancer
Cancer patients
Care and treatment
China
Coronavirus Infections - prevention & control
Coronavirus Infections - transmission
Coronavirus Infections - virology
COVID-19
Disease
Disease control
Epidemics
Health care
Hematology
Humans
Infection
Infection Control - methods
Infection Control - standards
Infections
Infectious Disease Transmission, Patient-to-Professional - prevention & control
Neoplasms - therapy
Neoplasms - virology
Pandemics
Pandemics - prevention & control
Patient Care - standards
Pneumonia, Viral - prevention & control
Pneumonia, Viral - transmission
Pneumonia, Viral - virology
Practice Guidelines as Topic - standards
Prevention
SARS-CoV-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since early 2020, the SARS-CoV-2 pandemic has a massive impact on health care systems worldwide. Patients with malignant diseases are assumed to be at increased risk for a worse outcome of SARS-CoV-2 infection, and therefore, guidance regarding prevention and management of the infection as well as safe administration of cancer-therapy is required. Here, we provide recommendations for the management of patients with malignant disease in the times of COVID-19. These recommendations were prepared by an international panel of experts and then consented by the EHA Scientific Working Group on Infection in Hematology. The primary aim is to enable clinicians to provide optimal cancer care as safely as possible, since the most important protection for patients with malignant disease is the best-possible control of the underlying disease.
ISSN:0887-6924
1476-5551
DOI:10.1038/s41375-020-0832-y